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M anaged care strives to limit health care spend- ing. This is good when unnecessary practices, 
administrative waste, fraud, and other abuses are 
eliminated. This  bad when lifesaving therapy is 
withheld for financial reasons. The cost of health 
care provision depends on the frequency of referral 
to specialized care. In a timely and innovative article 
published in this issue, Starr and others 1 examine 
the relationship between referral sources and mor- 
tality rates. The results, the investigators contend, 
were better in a managed care plan than in a 
traditional fee-for-service (FFS) system. Manage- 
ment consensus conferences led to fewer coronary 
balloon angioplasties, fewer catheterization labora- 
tory complications, fewer emergency operations, 
and fewer coronary artery reoperations. The policies 
formulated by health maintenance organization 
(HMO) physicians resulted in lower hospital mor- 
tality rates for managed care patients. 
There are no perfect studies; this one is faulted by 
incomplete data. The multivariable model could not 
explain two thirds of the in-hospital mortality differ- 
ences between the HMO and FFS cohorts. Presum- 
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ably, other unmeasured factors hold the larger share 
of risk for the observed mortality rates. The final 
regression model included only 43% of the 8483 
patients studied. The populations erved by both 
HMO and FFS plans could not be defined. There- 
fore, we do not know about exclusion criteria or 
what happened to the patients with severe coronary 
atherosclerosis who were not referred for revascu- 
larization. Were any of these patients afforded a 
second opinion as they are in a typical FFS system? 
We do know that the HMO patients who were 
admitted with a diagnosis of myocardial infarction 
incurred the same mortality rates as FFS patients. 
Retention rates in the area and crossover rates from 
managed care to commercial insurance or vice versa 
are not known. Although perioperative mortality 
was significantly lower in the HMO cohort, long- 
term outcome was identical in the 77% of patients 
for whom follow-up information was obtained. 
Notwithstanding these deficiencies, the fact remains 
that, after adjustments for demographic, linical, and 
angiographic differences, patients treated in an HMO 
managed care plan had significantly lower hospital 
mortality for coronary artery operations. Do the refer- 
ral practices explain the differences in results? The 
answer may lie in the cardiac surgery/angioplasty e~ 
lection criteria found in the appendix of the article. 
In addition to patients with left main disease and 
patients with valve disease plus coronary atheroscle- 
rosis, the surgery referral guidelines pecify patients 
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with two- or three-vessel disease and moderate left 
ventricular dysfunction and patients with multivessel 
disease with recurrent angina despite optimal med- 
ical treatment. There is no mention of ischemia, 
pathoanatomic characteristics, myocardial jeopardy, 
or vein graft atherosclerosis, all of which have more 
prognostic importance than symptoms. These surgi- 
cal criteria adhere to recommendations from the 
Coronary Artery Surgery Study (CASS) randomized 
trial, which were published in 1983. 2 As you recall, 
these CASS medical and surgical patients had sim- 
ilar 5-year results, which prompted the conclusion 
that patients could safely defer bypass urgery until 
their symptoms worsened to the point that surgical 
palliation was required. Patients enrolled in the 
clinical trial had no or minimal symptoms and 
represented less than 5% of the population who 
underwent coronary arteriography. Later on, a 10- 
year follow-up confirmed the early CASS report hat 
patients with left ventricular dysfunction derived 
long-term benefit from surgical treatment, whereas 
patients with mild angina nd normal eft ventricular 
function did not benefit from surgery. 3 However, the 
original 780 randomized patients were at low risk, as 
evidenced by absence of proximal eft anterior de- 
scending coronary artery disease in 69%, three- 
vessel disease in only 33%, and absence of exercise- 
induced myocardial ischemia in 40%. Only 16% of 
the surgically treated patients received internal tho- 
racic artery grafts, and 40% of those randomized to 
medical treatment were operated on within the first 
10 years. Extrapolation of these CASS results to the 
management of all patients with severe coronary 
atherosclerosis today is not justified and constitutes 
withholding potentially lifesaving treatment. 
The HMO managed care surgical criteria failed to 
take into account he conclusions from the Euro- 
pean Collaborative Study, which demonstrated im- 
proved surgical survival for patients with three- 
vessel disease and normal left ventricular function 
and for those with two- or three-vessel disease that 
involved the proximal eft anterior descending cor- 
onary artery. 4 The anterior descending coronary 
artery is more important prognostically than any of 
the other three major coronary arteries. The influ- 
ence of the conduit used to revascularize the ante- 
rior descending coronary artery has now been well 
documented: internal thoracic artery bypass grafting 
to the anterior descending coronary artery, which 
was also an independent risk factor in this study, 
reduces in-hospital mortality. 5 However, only ap- 
proximately half of each comparative group had 
internal thoracic artery grafting. Internal thoracic 
artery use is a more important predictor of survival 
than progression of native coronary atherosclerosis 
and, with few exceptions, should not be withheld 
from any subset of patients. 6 
Clinical trial populations often are of limited size 
and unrelated to everyday clinical practice. The 
CASS registry, in contrast to the randomized pro- 
spective study, contains data on approximately 
25,000 patients. Reports from this registry showed 
significant 4- to 6-year survivals markedly in favor of 
surgery over medical treatment for subsets of pa- 
tients with left-main equivalent, 7 three-vessel dis- 
ease with mild angina, 8poor left ventricular func- 
tion, 9 left ventricular aneurysm and three-vessel 
disease, 1° patients with multivessel disease and con- 
comitant peripheral vascular disease, 11 and patients 
65 years of age or older. 12 In patients with severe 
coronary atherosclerosis, myocardial revasculariza- 
tion should precede noncardiac surgery whenever 
feasible. CASS registry reports have also shown 
greater freedom from new myocardial infarction 
and sudden death among patients treated surgically 
compared with those treated medically. 
Today, coronary balloon a gioplasty may be rec- 
ommended for all but the most diffuse, complicated 
forms of coronary atherosclerosis. Except in patients 
with diabetes, the short-term survival for angioplasty 
compared with surgery in multivessel disease is 
about the same.* The costs of coronary balloon 
angioplasty and surgical revascularization are equiv- 
alent in 3 to 5 years after the initial therapy. The 
HMO criteria for coronary balloon angioplasty are 
conservative but appropriate. The HMO managed 
care policies eliminated cardiology self-referral. 
This will improve the economics of treatment, but 
self-referral per se is not necessarily dangerous. 
Previous balloon angioplasty was actually protective 
against coronary artery surgery mortality. Only a 
catheterization laboratory emergency increased the 
risk of surgery. Starr and others 1infer that unstruc- 
tured referral for coronary balloon angioplasty re- 
suited in more catheterization laboratory complica- 
tions. As a percentage of overall revascularization, 
the number of angioplasties performed in the HMO 
managed care plan was significantly less than in the 
FFS system. Patients referred for angioplasty in the 
* BARI Investigators. The Bypass Angioplasty Revascularization 
Investigation (BARI): five-year mortality and morbidity in a 
randomized study comparing CABG and PTCA in patients 
with multivessel coronary disease. Submitted for publication. 
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FFS sector may have been at higher risk than 
patients in the managed care plan. 
Thus the answer to the perioperative mortality 
differences may be found in the exclusion criteria. 
Inasmuch as there were significantly fewer angio- 
plasties and lower catheterization laboratory com- 
plications in the HMO cohort, fewer emergency oper- 
ations were done, which explains some of the mortality 
reduction. The discrepancy in the reoperation rates, 
however, is not explained satisfactorily. Reoperation 
cases were referred less often from the HMO source. 
How were these patients with previous coronary artery 
surgery treated? Most patients are reoperated on for 
vein graft atherosclerosis. Late vein graft narrowing 
may be treated by angioplasty, but the early restenosis 
rate is about 50% and the subsequent cardiac event 
rate is high.* Patients with untreated atherosclerosis of 
the anterior descending coronary artery vein graft have 
a significantly worse prognosis than patients with na- 
tive vessel anterior descending coronary artery disease 
or atherosclerosis n grafts to other coronary arteries 
and should be considered high priority for revascular- 
ization. 13 
Despite the fact that the data do not completely 
support the conclusions, this article should serve as 
another wake-up call to get involved. A manage- 
ment consensus approach to myocardial revascular- 
ization is ideal and has the advantage of drawing 
from broader experience in selecting individualized 
care. In this era of rapid scientific advance, a good 
database is essential to refine selection criteria for 
complicated technology. The drawbacks occur when 
strict selection criteria supplant clinical judgment 
and when financial risk determines the referral 
status. As the managed care revolution sweeps the 
country, better communication about health care 
management will be required. The HMO is not the 
only vehicle for coordinated care. Any group prac- 
tice has the ability to select appropriate treatment, 
control cost, and monitor quality. 
* Rabbani RR, Bell MR, Grill DE, Frantz RP, Simari RD, 
Holmes DR Jr. Follow-up after successful percutaneous coro- 
nary angioplasty of saphenous vein graft disease and the impor- 
tance of long-term assessment. Submitted for publication. 
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